Poly (L-&gamma;-glutamylglutamine) nanoparticles enhance drug accumulation in resistant cells

LIU Kai; CHEN Jing; WANG Jing; YU Lei; ZHU Jian-zhong; WANG Yi-ting

Issue 6

Jan. 2014

Turn off MathJax

Article Contents

Article Navigation > Journal of East China Normal University (Natural Sciences) > 2013 > (6): 141-149

LIU Kai, CHEN Jing, WANG Jing, YU Lei, ZHU Jian-zhong, WANG Yi-ting. Poly (L-γ-glutamylglutamine) nanoparticles enhance drug accumulation in resistant cells[J]. Journal of East China Normal University (Natural Sciences), 2013, (6): 141-149.

Citation:

LIU Kai, CHEN Jing, WANG Jing, YU Lei, ZHU Jian-zhong, WANG Yi-ting. Poly (L-γ-glutamylglutamine) nanoparticles enhance drug accumulation in resistant cells[J]. Journal of East China Normal University (Natural Sciences), 2013, (6): 141-149.

Citation:

PDF( 2072 KB)

Poly (L-γ-glutamylglutamine) nanoparticles enhance drug accumulation in resistant cells

1.
Institutes for Advanced interdisciplinary Research, East China Normal University, Shanghai 200062, China

Received Date: 2013-01-01
Rev Recd Date: 2013-04-01
Publish Date: 2013-11-25

Abstract

Abstract

This work investigated the antitumor efficacy of poly (L--glutamylglutamine) (PGG) prodrug in multidrug resistant (MDR) cancer cells and the possible mechanisms. The A549 cell line was induced to become multidrug resistant. A549 was applied to evaluate the effect of PGG-Dox on intracellular accumulation and retention of Dox.Endocytosis inhibition studies and transmission electron microscope assay were used to investigate the mechanisms of cellular PGG-Dox uptake. Confocal laser scanning microscopy was performed to confirm the drug accumulation. Treatment of MDR cells with PGG-Dox resulted in significantly enhanced drug accumulation and retention after the end of treatment compared with free Dox. Endocytosis inhibition studies showed pinocytosis is the mainly pathway in the elevated membrane permeability of the PGG-Dox. These demonstrated that Dox conjugate with PGG NPs effectively bypass the multidrug resistance. Our PGG DDS may be considered as an attractive and promising delivery system to overcome multidrug resistance.
- multidrug resistance,
- polymer drug delivery system,
- nanotechnology,
- nanomedicine

FullText(HTML)

References(1)

References

[1]

［1］ MINOTTI G, MENNA P, SALVATORELLI E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity［J］. Pharmacological Reviews, 2004,56: 185-229. 

［2］ DAVE B, CHANG J. Treatment resistance in stem cells and breast cancer［J］. Journal of Mammary Gland Biology and Neoplasia, 2009,14: 79-82. 

［3］ BORST P, ELFERINK R O. Mammalian ABC transporters in health and disease［J］. Annual Review of Biochemistry, 2002,71: 537-592. 

［4］ BROXTERMAN H J, GOTINK K J, VERHEUL H M. Understanding the causes of multidrug resistance in cancer: A comparison of doxorubicin and sunitinib［J］. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2009(12): 114-126. 

［5］ AMBUDKAR S V, KIMCHI-SARFATY C, SAUNA Z E, et al. P-glycoprotein: From genomics to mechanism. Oncogene［J］. 2003,22: 7468-7485. 

［6］ GOTTESMAN M M, FOJO T, BATES S E. Multidrug resistance in cancer: Role of ATP-dependent transporters［J］. Nature Reviews. Cancer, 2002(2): 48-58. 

［7］ MISRA R, ACHARYA S, SAHOO S K. Cancer nanotechnology: Application of nanotechnology in cancer therapy［J］. Drug Discovery Today, 2010,15: 842-850. 

［8］ SHAPIRA A, LIVNEY Y D, BROXTERMAN H J, et al. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance［J］. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2011,14: 150-163. 

［9］ DUNCAN R. Polymer conjugates as anticancer nanomedicines［J］. Nature Reviews Cancer. 2006(6): 688-701. 

［10］ CHITHRANI B D, GHAZANI A A, CHAN W C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells［J］. Nano Letters, 2006(6): 662-668. 

［11］ CHITHRANI B D, CHAN W C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes［J］. Nano Letters, 2007(7): 1542-1550. 

［12］ WONG H L, BENDAYAN R, RAUTH A M, et al. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system［J］. The Journal of Pharmacology and Experimental Therapeutics, 2006,317: 1372-1381. 

［13］ BONOMI P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer［J］. Expert Review of Anticancer Therapy, 2007(7): 415-422. 

［14］ DUNCAN R, VICENT M J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities［J］. Advanced Drug Delivery Reviews, 2010,62: 272-282. 

［15］ ETRYCH T, SIROVA M, STAROVOYTOVA L, et al. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release［J］. Molecular Pharmaceutics, 2010(7): 1015-1026. 

［16］ MILLER K, ELDAR-BOOCK A, POLYAK D, et al. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model［J］. Molecular Pharmaceutics, 2011(8): 1052-1062. 

［17］ VAN S, DAS S K, WANG X, et al. Synthesis, characterization, and biological evaluation of poly(L-gamma-glutamyl-glutamine)- paclitaxel nanoconjugate［J］. International Journal of Nanomedicine, 2010(5): 825-837. 

［18］ WANG X, ZHAO G, VAN S, et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts［J］. Cancer Chemotherapy and Pharmacology, 2010,65: 515-526. 

［19］ YANG D, VAN S, JIANG X, et al. Novel free paclitaxel-loaded poly(L-gamma-glutamylglutamine)-paclitaxel nanoparticles［J］. International Journal of Nanomedicine, 2011(6): 85-91. 

［20］ YANG D, VAN S, SHU Y, et al. Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy［J］. International Journal of Nanomedicine, 2012(7): 581-589. 

［21］ PAJIC M, IYER J K, KERSBERGEN A, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer［J］. Cancer Research, 2009,69: 6396-6404. 

［22］ DUNCAN R. Polymer therapeutics as nanomedicines: New perspectives ［J］. Current Opinion in Biotechnology, 2011,22: 492-501. 

［23］ WAN C P, LETCHFORD K, JACKSON J K, et al. The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance［J］. Int J Nanomedicine, 2013(8): 379-391. 

［24］ CASCORBI I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations［J］. Handb Exp Pharmacol, 2011,201: 261-283.

Relative Articles

Supplements(0)

Cited By

Proportional views